Evidence map›Paper›PMID 39753703›Full record

ReviewCurrent obesity reports2025

Long-Term Efficacy and Safety of Nutritional and Pharmacological Strategies for Obesity.

Luigi Barrea, Mara Boschetti, Elena Gangitano, Valeria Guglielmi, Ludovica Verde, Giovanna Muscogiuri

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current obesity reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Luigi BarreaDipartimento di Benessere, Nutrizione e Sport, Centro Direzionale, Università Telematica Pegaso, Via Porzio, Isola F2, Naples, 80143, Italy.ORCID http://orcid.org/0000-0001-9054-456X
Mara BoschettiEndocrinology Unit, Department of Internal Medicine and Medical Specialties (DiMI), University of Genova, Genoa, 16132, Italy.
Elena GangitanoDepartment of Experimental Medicine, Sapienza University of Rome, Rome, 00161, Italy.
Valeria GuglielmiDepartment of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Ludovica VerdeDipartimento di Medicina Clinica e Chirurgia, Centro Italiano per la cura e il Benessere del Paziente con Obesità (C.I.B.O),Università degli Studi di Napoli Federico II, Via Sergio Pansini 5, Naples, 80131, Italy.
Giovanna MuscogiuriDipartimento di Medicina Clinica e Chirurgia, Centro Italiano per la cura e il Benessere del Paziente con Obesità (C.I.B.O),Università degli Studi di Napoli Federico II, Via Sergio Pansini 5, Naples, 80131, Italy. giovanna.muscogiuri@unina.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThis review examines the long-term efficacy and safety of various nutritional and pharmacological strategies for managing obesity. The focus is on the Mediterranean diet (MedDiet), very low-energy ketogenic therapy (VLEKT), and pharmacological interventions such as naltrexone/bupropion and liraglutide. Given the chronic nature of obesity, understanding the sustainability and impact of these treatments over time is critical. RECENT

findingsThe MedDiet has shown significant benefits for cardiovascular health and moderate long-term weight loss, though it does not always outperform other diets in terms of weight reduction. VLEKT is highly effective for rapid weight loss, but concerns remain about its long-term sustainability. Pharmacological treatments, including naltrexone/bupropion and liraglutide, have shown promise in promoting significant weight loss and improving metabolic markers. However, issues related to long-term adherence and potential side effects need further exploration. Both nutritional and pharmacological strategies offer valuable tools in obesity management. While treatments like VLEKT and pharmacological options provide significant short-term benefits, the MedDiet remains a sustainable long-term approach. The long-term efficacy and safety of naltrexone/bupropion and liraglutide require more investigation to address challenges in weight maintenance and side effects. Further studies are needed to establish the optimal duration and combination of these therapies for sustained obesity management.

Indexed as

Anti-Obesity AgentsBupropionDiet, KetogenicDiet, MediterraneanLiraglutideNaltrexoneObesityWeight LossDrug CombinationsHumansTreatment OutcomeAnti-Obesity AgentsBupropionDrug CombinationsLiraglutideNaltrexoneNaltrexone-Bupropion combinationAnti-obesity DrugsGLP1-analoguesKetogenic dietLiraglutideLong-termMediterranean dietNaltrexone/bupropionNutritionObesityWeight loss

Identifiers

PMID39753703

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.